• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胸腺癌与胸内类癌患者临床特征和生存的比较。

Comparison of clinical features and survival between thymic carcinoma and thymic carcinoid patients.

机构信息

Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.

出版信息

Eur J Cardiothorac Surg. 2017 Jul 1;52(1):33-38. doi: 10.1093/ejcts/ezx037.

DOI:10.1093/ejcts/ezx037
PMID:28419205
Abstract

OBJECTIVES

Thymic carcinoma (TC) and thymic carcinoid (TCD) are aggressive thymic epithelial neoplasms with a poor prognosis. Due to rarity, little is known about their comparative clinical characteristics, treatment outcomes and patterns of relapse.

METHODS

A retrospective cohort study was performed on 287 patients with TC and 56 patients with TCD who were treated at the Shanghai Chest Hospital between February 2003 and April 2014. Patient demographics, tumour stage, treatment, pathologic findings and postoperative outcomes were compared between the two tumour types using both multivariable Cox regression analysis and propensity-matched analysis.

RESULTS

Compared to patients with TC, significantly more patients with TCD were male, had larger tumours, and displayed a greater proportion of lymph node metastases. However, overall survival was similar (60.7% 5-year survival for TC, 80.7% for TCD, P  = 0.159), as was disease-free survival (41.1% 5-year survival for TC, 37.6% for TCD, P  = 0.696) and patterns of relapse. Multiple Cox regression analysis identified younger patients [hazard ratio (HR) 1.018; 95% confidence interval (CI) 1.000-1.035; P  = 0.047], more completeness of resection (HR 1.424; 95% CI 1.105-1.836; P  = 0.006), adjuvant radiotherapy (HR 0.455; 95% CI 0.276-0.751; P  = 0.002), and no adjuvant chemotherapy (HR 1.799; 95% CI 1.017-3.183; P  = 0.044) as independent factors predicting better overall survival. Completeness of resection (HR 1.258; 95% CI 1.022-1.548; P  = 0.031) and TNM stage (HR 1.479; 95% CI 1.107-1.977; P  = 0.008) were independent predictors of disease-free survival. Propensity matching produced 46 patients in each group and no significant difference on overall survival or disease-free survival was found.

CONCLUSIONS

Patients with TCD have discrete features but share a similar clinical course to those with TC. The importance of complete resection in both of these thymic malignancies is emphasized. Further investigation at multiple centers with the longer follow-up data is required to substantiate our conclusion.

摘要

目的

胸腺癌(TC)和胸类癌(TCD)是侵袭性胸上皮肿瘤,预后较差。由于其罕见性,对于其比较的临床特征、治疗结果和复发模式知之甚少。

方法

对 2003 年 2 月至 2014 年 4 月在上海胸科医院接受治疗的 287 例 TC 患者和 56 例 TCD 患者进行了回顾性队列研究。使用多变量 Cox 回归分析和倾向匹配分析比较了两种肿瘤类型的患者人口统计学、肿瘤分期、治疗、病理发现和术后结果。

结果

与 TC 患者相比,TCD 患者中男性更多,肿瘤更大,淋巴结转移比例更高。然而,总生存率相似(TC 为 60.7%,5 年生存率;TCD 为 80.7%,P=0.159),无病生存率也相似(TC 为 41.1%,5 年生存率;TCD 为 37.6%,P=0.696)和复发模式。多变量 Cox 回归分析确定了年龄较小的患者(风险比 [HR] 1.018;95%置信区间 [CI] 1.000-1.035;P=0.047)、更完整的切除(HR 1.424;95%CI 1.105-1.836;P=0.006)、辅助放疗(HR 0.455;95%CI 0.276-0.751;P=0.002)和无辅助化疗(HR 1.799;95%CI 1.017-3.183;P=0.044)是总生存率的独立预测因素。完全切除(HR 1.258;95%CI 1.022-1.548;P=0.031)和 TNM 分期(HR 1.479;95%CI 1.107-1.977;P=0.008)是无病生存率的独立预测因素。

结论

TCD 患者具有不同的特征,但与 TC 患者的临床过程相似。强调了在这两种胸腺恶性肿瘤中完全切除的重要性。需要在多个中心进行进一步的研究,并结合更长的随访数据来证实我们的结论。

相似文献

1
Comparison of clinical features and survival between thymic carcinoma and thymic carcinoid patients.胸腺癌与胸内类癌患者临床特征和生存的比较。
Eur J Cardiothorac Surg. 2017 Jul 1;52(1):33-38. doi: 10.1093/ejcts/ezx037.
2
Improved survival with postoperative radiotherapy in thymic carcinoma: A propensity-matched analysis of Surveillance, Epidemiology, and End Results (SEER) database.胸腺癌术后放疗可提高生存率:基于监测、流行病学和最终结果(SEER)数据库的倾向匹配分析
Lung Cancer. 2017 Jun;108:161-167. doi: 10.1016/j.lungcan.2017.03.020. Epub 2017 Mar 31.
3
Effect of clinicopathologic features on survival of patients with thymic carcinomas and thymic neuroendocrine tumors: A population-based analysis.胸腺癌和胸内神经内分泌肿瘤患者的临床病理特征对生存的影响:基于人群的分析。
Curr Probl Cancer. 2019 Oct;43(5):411-420. doi: 10.1016/j.currproblcancer.2019.03.004. Epub 2019 Mar 29.
4
Prognostic Factor of Completely Resected and Pathologic T3 N0 M0 Thymic Epithelial Tumor.完全切除和病理 T3N0M0 胸腺癌的预后因素。
Ann Thorac Surg. 2021 Apr;111(4):1164-1173. doi: 10.1016/j.athoracsur.2020.06.078. Epub 2020 Sep 2.
5
What is the role of lymph nodal metastases and lymphadenectomy in the surgical treatment and prognosis of thymic carcinomas and carcinoids?淋巴结转移及淋巴结清扫术在胸腺癌和类癌的外科治疗及预后中起什么作用?
Interact Cardiovasc Thorac Surg. 2014 Dec;19(6):1054-8. doi: 10.1093/icvts/ivu281. Epub 2014 Sep 4.
6
Multimodality therapy for locally advanced thymomas: A propensity score-matched cohort study from the European Society of Thoracic Surgeons Database.局部晚期胸腺瘤的多模态治疗:一项来自欧洲胸外科医师协会数据库的倾向评分匹配队列研究。
J Thorac Cardiovasc Surg. 2016 Jan;151(1):47-57.e1. doi: 10.1016/j.jtcvs.2015.08.034. Epub 2015 Aug 15.
7
Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database.胸腺肿瘤:一项基于欧洲心胸外科医师协会数据库的预后因素队列研究
Eur J Cardiothorac Surg. 2014 Sep;46(3):361-8. doi: 10.1093/ejcts/ezt649. Epub 2014 Jan 30.
8
Treatment Modalities and Outcomes in Patients With Advanced Invasive Thymoma or Thymic Carcinoma: A Retrospective Multicenter Study.晚期侵袭性胸腺瘤或胸腺癌患者的治疗方式及预后:一项回顾性多中心研究
Am J Clin Oncol. 2016 Apr;39(2):120-5. doi: 10.1097/COC.0000000000000024.
9
Thymic carcinoma: 30 cases at a single institution.胸腺癌:一家机构的30例病例。
J Thorac Oncol. 2008 Mar;3(3):265-9. doi: 10.1097/JTO.0b013e3181653c71.
10
Thymic Neuroendocrine Tumors and Thymic Carcinoma: Demographics, Treatment, and Survival.胸神经内分泌肿瘤和胸腺癌:人口统计学、治疗和生存。
Innovations (Phila). 2020 Sep/Oct;15(5):468-474. doi: 10.1177/1556984520949287. Epub 2020 Sep 16.

引用本文的文献

1
Narrative review of the prognostic significance of primary tumor size in thymic epithelial tumor.胸腺上皮肿瘤中原发肿瘤大小的预后意义的叙述性综述。
Mediastinum. 2025 Jun 25;9:14. doi: 10.21037/med-25-3. eCollection 2025.
2
A Randomized clinical trial evaluating the impact on survival and quality of life of Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).一项评估镥[Lu]依多曲肽与依维莫司对肺和胸腺神经内分泌肿瘤患者生存及生活质量影响的随机临床试验:LEVEL研究(GETNE T-2217)
BMC Cancer. 2025 Apr 4;25(1):613. doi: 10.1186/s12885-025-13941-3.
3
Long-term survival and prognosis after surgical treatment of patients with thymic carcinoma: a retrospective analysis.
胸腺癌患者手术治疗后的长期生存及预后:一项回顾性分析
J Thorac Dis. 2024 Nov 30;16(11):7582-7591. doi: 10.21037/jtd-24-1056. Epub 2024 Nov 13.
4
Clinical characteristics and prognosis of primary thymic adenocarcinoma: A single-center retrospective analysis.原发性胸腺癌的临床特征和预后:单中心回顾性分析。
Thorac Cancer. 2024 Aug;15(24):1815-1821. doi: 10.1111/1759-7714.15407. Epub 2024 Jul 25.
5
Analysis of 25 surgical cases of thymic neuroendocrine tumors and thymic carcinoma.胸腺神经内分泌肿瘤和胸腺癌 25 例手术分析。
J Cardiothorac Surg. 2024 Apr 16;19(1):225. doi: 10.1186/s13019-024-02723-w.
6
Effect of open versus video-assisted thoracoscopy on perioperative outcomes and survival for cases of thymic carcinomas and thymic neuroendocrine tumors.开胸与电视辅助胸腔镜手术治疗胸腺癌和胸腺神经内分泌肿瘤围手术期结局和生存的影响。
World J Surg Oncol. 2023 Oct 16;21(1):329. doi: 10.1186/s12957-023-03210-7.
7
Surgical treatment of intermediate to high grade thymic neuroendocrine neoplasms: case series of five patients and literature review.中高级别胸腺神经内分泌肿瘤的外科治疗:5例病例系列及文献综述
Transl Cancer Res. 2022 Oct;11(10):3535-3547. doi: 10.21037/tcr-22-1150.
8
CD117, BAP1, MTAP, and TdT Is a Useful Immunohistochemical Panel to Distinguish Thymoma from Thymic Carcinoma.CD117、BAP1、MTAP和TdT是用于区分胸腺瘤和胸腺癌的有用免疫组织化学检测组合。
Cancers (Basel). 2022 May 5;14(9):2299. doi: 10.3390/cancers14092299.
9
Thymic Carcinomas-A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group.胸腺癌——国际胸腺癌兴趣小组胸腺癌工作组对近期进展的简要多学科更新。
J Thorac Oncol. 2022 May;17(5):637-650. doi: 10.1016/j.jtho.2022.01.021. Epub 2022 Feb 25.
10
Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors.生长抑素受体2表达、68Ga-DOTATATE PET扫描与胸腺上皮肿瘤奥曲肽治疗的相关性
Front Oncol. 2022 Feb 7;12:823667. doi: 10.3389/fonc.2022.823667. eCollection 2022.